{"id":"NCT01623115","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-04","completion":"2014-12","firstPosted":"2012-06-19","resultsPosted":"2015-11-04","lastUpdate":"2016-02-08"},"enrollment":486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Lipid Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg/Up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\n\nPrimary Objective of the study:\n\nTo evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points\n* To evaluate the effects of alirocumab on other lipid parameters\n* To evaluate the safety and tolerability of alirocumab","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","timeFrame":"From Baseline to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":9.1,"sd":2.2},{"arm":"Alirocumab 75 mg/Up to 150 mg Q2W","deltaMin":-48.8,"sd":1.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":91,"countries":["United States","Austria","Canada","Czechia","Denmark","France","Israel","Netherlands","Norway","Russia","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24842558","26330422","34298554","30183102","28964736","28391886","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":163},"commonTop":["Injection site reaction","Nasopharyngitis","Upper respiratory tract infection","Influenza","Arthralgia"]}}